Maximizing survival in metastatic castration-resistant prostate cancer (mCRPC)

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 10 Jan 2014
Views: 3338
Dr John Fitzpatrick - Irish Cancer Society & University College Dublin, Dublin, Ireland

Within the last 4 years, the prognosis of metastatic castration-resistant prostate cancer (mCRPC) has dramatically changed with 5 novel therapies demonstrating a survival benefit in phase III clinical trials.

The challenge for physicians is now to integrate this broad armamentarium rationally in daily practice and appropriately tailor therapy to optimise treatment outcomes and benefits of each individual patient. Our common goal remains to maintain patients’ quality of life by delaying disease progression and complications whilst prolonging survival.

The objectives of this symposium are:

• to discuss the current landscape of treatment options in mCRPC

• to better understand the pathophysiology of the disease to guide treatment choices

• to share views on how to best sequence or combine available therapies


Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.